Soraya Maria Menezes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Soraya Maria Menezes has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Johan Van Weyenbergh
KU Leuven
10 shared publications - Tim Dierckx
KU Leuven, Department of Microbiology, Immunology and Transplantation, Molecular Genetics and Therapeutics in Virology and Oncology Research Group, Rega Institute, Leuven Cancer Institute, 3000 Leuven, Belgium
5 shared publications - Ricardo Khouri
Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Rua Waldemar Falcão, 121, Candeal, Salvador 40296-710, Bahia, Brazil
4 shared publications - Achilea Lisboa Bittencourt
Department of Pathology, Federal University of Bahia, Brazil
2 shared publications - André Báfica
Laboratory of Immunobiology, Department of Microbiology, Immunology and Parasitology, Federal University of Santa Catarina, Florianópolis 88040-900, Brazil
2 shared publications - Anne-Mieke Vandamme
Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Institute for the Future, KU Leuven, Leuven, Belgium
2 shared publications
Latest Publications
- Open Access
- 19 February 2026
- Published by Springer Nature in Research Square
SARS-CoV-2 Mpro protease as a biomarker and therapeutic target in Long COVID: a real-world prospective cohort study
Long COVID affects 400 million people worldwide, for whom predictive biomarkers and effective therapies are urgently needed. Herein, we investigate SARS-CoV-2 viral RNAs as candidate biomarkers and therapeutic targets. Combining whole blood digital transcriptomics and plasma proteomics, viral RNAs significantly correlated with platelet-expressed genes/proteins and complement/coagulation pathways. Likewise, SARS-CoV-2 ORF3a, ORF8 , M and antisense RNAs were significantly enriched in purified platelets. Mpro viral RNA was increased in patients with lower self-reported fitness, which could be reverted by Paxlovid (Nirmatrelvir/Ritonavir) treatment. Using a novel, cloud-based real-time analysis of personalized symptom scores, we found significant clinical benefit of Paxlovid, parallelled by a rapid decline in neurodamage/astrogliosis markers (NFL/GFAP). Multivariate logistic regression revealed antiviral but not antiplatelet treatment as independent predictor of clinical recovery in a real-world Long COVID cohort with long-term follow-up. Platelet-expressed biomarkers of Paxlovid response ( IL12A/HDAC5) were validated in a placebo-controlled clinical trial (PROLIFIC). In conclusion, our results provide mechanistic and druggable links between major Long COVID disease mechanisms: viral persistence, platelet/coagulation defects, and neurodamage.
- 19 February 2026
- Published by Springer Nature in Research Square
Open AccessSARS-CoV-2 Mpro protease as a biomarker and therapeutic target in Long COVID: a real-world prospective cohort study
Long COVID affects 400 million people worldwide, for whom predictive biomarkers and effective therapies are urgently needed. Herein, we investigate SARS-CoV-2 viral RNAs as candidate biomarkers and therapeutic targets. Combining whole blood digital transcriptomics and plasma proteomics, viral RNAs significantly correlated with platelet-expressed genes/proteins and complement/coagulation pathways. Likewise, SARS-CoV-2 ORF3a, ORF8 , M and antisense RNAs were significantly enriched in purified platelets. Mpro viral RNA was increased in patients with lower self-reported fitness, which could be reverted by Paxlovid (Nirmatrelvir/Ritonavir) treatment. Using a novel, cloud-based real-time analysis of personalized symptom scores, we found significant clinical benefit of Paxlovid, parallelled by a rapid decline in neurodamage/astrogliosis markers (NFL/GFAP). Multivariate logistic regression revealed antiviral but not antiplatelet treatment as independent predictor of clinical recovery in a real-world Long COVID cohort with long-term follow-up. Platelet-expressed biomarkers of Paxlovid response ( IL12A/HDAC5) were validated in a placebo-controlled clinical trial (PROLIFIC). In conclusion, our results provide mechanistic and druggable links between major Long COVID disease mechanisms: viral persistence, platelet/coagulation defects, and neurodamage.
- Open Access
- 21 October 2025
- Published by Springer Nature in Research Square
Multi-level systems analysis identifies XPO1 as a druggable target linked to NFκB activation, proliferation, tumor clonality and long-term survival in Adult T-cell Leukemia
Adult T-cell leukemia (ATL), an aggressive malignancy triggered by human T-cell leukemia virus-1 (HTLV-1), has a dismal prognosis and limited therapeutic options. Here, we investigate the nuclear export protein XPO1 as a critical driver of ATL proliferation and a promising therapeutic target. We used a multi-level approach, combining systems biology analysis of three independent ATL patient cohorts with in vitro functional validation. Our systems analysis revealed that XPO1 expression is significantly elevated and differentially spliced in acute ATL, and is central to a pro-proliferative gene module, positively correlated with both the ATL transcriptional signature and tumor clonality. This ex vivo link was confirmed in vivo in four unique long-term surviving patients, for which successful therapy with IFN-α+AZT led to a concurrent decrease in XPO1 and key proliferation marker PCNA . Furthermore, we demonstrated that pharmacological inhibition of XPO1 with the clinical-stage compound Selinexor (KPT-330) and a related SINE compound, KPT-185, decreased proliferation and induced apoptosis in HTLV-1-transformed cells. Mechanistically, XPO1 inhibition exerted its anti-tumor effect by dismantling the pro-survival NF-κB pathway. Our combined findings establish XPO1 as a relevant therapeutic target in ATL and suggest its possible use as a biomarker for therapeutic response.
- 21 October 2025
- Published by Springer Nature in Research Square
Open AccessMulti-level systems analysis identifies XPO1 as a druggable target linked to NFκB activation, proliferation, tumor clonality and long-term survival in Adult T-cell Leukemia
Adult T-cell leukemia (ATL), an aggressive malignancy triggered by human T-cell leukemia virus-1 (HTLV-1), has a dismal prognosis and limited therapeutic options. Here, we investigate the nuclear export protein XPO1 as a critical driver of ATL proliferation and a promising therapeutic target. We used a multi-level approach, combining systems biology analysis of three independent ATL patient cohorts with in vitro functional validation. Our systems analysis revealed that XPO1 expression is significantly elevated and differentially spliced in acute ATL, and is central to a pro-proliferative gene module, positively correlated with both the ATL transcriptional signature and tumor clonality. This ex vivo link was confirmed in vivo in four unique long-term surviving patients, for which successful therapy with IFN-α+AZT led to a concurrent decrease in XPO1 and key proliferation marker PCNA . Furthermore, we demonstrated that pharmacological inhibition of XPO1 with the clinical-stage compound Selinexor (KPT-330) and a related SINE compound, KPT-185, decreased proliferation and induced apoptosis in HTLV-1-transformed cells. Mechanistically, XPO1 inhibition exerted its anti-tumor effect by dismantling the pro-survival NF-κB pathway. Our combined findings establish XPO1 as a relevant therapeutic target in ATL and suggest its possible use as a biomarker for therapeutic response.
- Open Access
- 29 April 2025
- Published by Springer Nature in Research Square
Multi-cohort cross-omics analysis reveals disease mechanisms and therapeutic targets in HTLV-1-associated myelopathy, a neglected retroviral neuroinflammatory disorder
HTLV-1 is an enigmatic retrovirus triggering a debilitating neuroinflammatory disease, HTLV-1-associated myelopathy (HAM), with unknown pathogenesis. Both HTLV-1 infection and HAM predominantly affect women and non-white neglected populations. HAM is lacking disease-modifying treatment, as current treatment is mostly symptomatic and inspired by either HIV-1 or multiple sclerosis therapeutic strategies. We used systems biology analyses of novel and publicly available data comprising (epi)genomics, transcriptomics, metabolomics and proteomics of multi-ancestry cohorts from a total of > 2500 People Living with HTLV-1 from 5 countries (Brazil, Peru, Japan, UK, US). Leveraging an unique admixed Brazilian cohort, genome-wide association study (GWAS) revealed African-specific variants in inflammasome sensor AIM2 with genome-wide significance (p < 5x10− 8). Suggestive loci (p > 5x10− 8) corresponding to metabolic, immune and neuronal genes were validated using published Japanese GWAS. Polygenic risk score and proviral load were independent disease predictors across ancestries. Systems biology analysis revealed neuronal/synaptic signaling, monocyte count, glucose/lipid metabolism, and neurocognition/depression as genetically linked to HAM. In silico drug screening identified estrogen blocker Fulvestrant as the top hit, while also confirming existing (pre)clinical data for HDAC inhibitors and immunosuppressants. Validated GWAS genes were overexpressed in HAM patients’ whole blood and CD4 T-cells, as well as in spinal cord astrocytes, oligodendrocytes, and microglia by single-cell RNAseq. We experimentally confirmed decreased ApoA1/lipid/cholesterol levels, higher monocyte levels and lower neurocognitive scores in multi-ancestry cohorts. We found striking biological similarities between retroviral Hbz/Tax overexpression, Hbz interactome and HAM multi-omics findings: enrichment for lipid/cholesterol metabolism, estrogen signaling, neurodegenerative diseases, and viral pathways including EBV, recently identified as the major driver of multiple sclerosis. In conclusion, our data-driven approach uncovers novel disease mechanisms and therapeutic targets, and a validated polygenic risk score allowing targeted surveillance for high-risk individuals. A strong molecular overlap to other neurodegenerative/neuroinflammatory diseases reveals shared neuropathogenic pathways between unrelated viruses.
- 29 April 2025
- Published by Springer Nature in Research Square
Open AccessMulti-cohort cross-omics analysis reveals disease mechanisms and therapeutic targets in HTLV-1-associated myelopathy, a neglected retroviral neuroinflammatory disorder
HTLV-1 is an enigmatic retrovirus triggering a debilitating neuroinflammatory disease, HTLV-1-associated myelopathy (HAM), with unknown pathogenesis. Both HTLV-1 infection and HAM predominantly affect women and non-white neglected populations. HAM is lacking disease-modifying treatment, as current treatment is mostly symptomatic and inspired by either HIV-1 or multiple sclerosis therapeutic strategies. We used systems biology analyses of novel and publicly available data comprising (epi)genomics, transcriptomics, metabolomics and proteomics of multi-ancestry cohorts from a total of > 2500 People Living with HTLV-1 from 5 countries (Brazil, Peru, Japan, UK, US). Leveraging an unique admixed Brazilian cohort, genome-wide association study (GWAS) revealed African-specific variants in inflammasome sensor AIM2 with genome-wide significance (p < 5x10− 8). Suggestive loci (p > 5x10− 8) corresponding to metabolic, immune and neuronal genes were validated using published Japanese GWAS. Polygenic risk score and proviral load were independent disease predictors across ancestries. Systems biology analysis revealed neuronal/synaptic signaling, monocyte count, glucose/lipid metabolism, and neurocognition/depression as genetically linked to HAM. In silico drug screening identified estrogen blocker Fulvestrant as the top hit, while also confirming existing (pre)clinical data for HDAC inhibitors and immunosuppressants. Validated GWAS genes were overexpressed in HAM patients’ whole blood and CD4 T-cells, as well as in spinal cord astrocytes, oligodendrocytes, and microglia by single-cell RNAseq. We experimentally confirmed decreased ApoA1/lipid/cholesterol levels, higher monocyte levels and lower neurocognitive scores in multi-ancestry cohorts. We found striking biological similarities between retroviral Hbz/Tax overexpression, Hbz interactome and HAM multi-omics findings: enrichment for lipid/cholesterol metabolism, estrogen signaling, neurodegenerative diseases, and viral pathways including EBV, recently identified as the major driver of multiple sclerosis. In conclusion, our data-driven approach uncovers novel disease mechanisms and therapeutic targets, and a validated polygenic risk score allowing targeted surveillance for high-risk individuals. A strong molecular overlap to other neurodegenerative/neuroinflammatory diseases reveals shared neuropathogenic pathways between unrelated viruses.
- Open Access
- 24 April 2024
- Published by Elsevier in The Lancet Microbe
- Vol. 5 (8) , 100849
Blood transcriptomic analyses reveal persistent SARS-CoV-2 RNA and candidate biomarkers in post-COVID-19 condition
- 24 April 2024
- Published by Elsevier in The Lancet Microbe
- Vol. 5 (8) , 100849
Open AccessBlood transcriptomic analyses reveal persistent SARS-CoV-2 RNA and candidate biomarkers in post-COVID-19 condition
- Open Access
- 18 December 2018
- Published by Wiley in International Journal of Cancer
- Vol. 144 (7) , 1664-1675
Decreased RORC expression and downstream signaling in HTLV‐1‐associated adult T‐cell lymphoma/leukemia uncovers an antiproliferative IL17 link: A potential target for immunotherapy?
Retinoic acid‐related drugs have shown promising pre‐clinical activity in Adult T‐cell Leukemia/Lymphoma, but RORC signaling has not been explored. Therefore, we investigated transcriptome‐wide interactions of the RORC pathway in HTLV‐1 and ATL, using our own and publicly available gene expression data for ATL and other leukemias. Gene expression data from ATL patients were analyzed using WGCNA to determine gene modules and their correlation to clinical and molecular data. Both PBMCs and CD4+ T‐Cells exhibited decreased RORC expression in four different ATL cohorts. A small subset of RORChi ATL patients was identified with significantly lower pathognomonic CADM1 and HBZ levels but similar levels of other ATL markers (CD4/CD25/CCR4), hinting at a less aggressive ATL subtype. An age‐dependent decrease in RORC expression was found in HTLV‐1‐infected individuals, but not in healthy controls, suggesting an early molecular event predisposing to leukemogenesis. Genes upstream of RORC signaling were members of a proliferative gene module (containing proliferation markers PCNA/Ki67), whereas downstream members clustered in an anti‐proliferative gene module. IL17C transcripts showed the strongest negative correlation to PCNA in both ATL cohorts, which was replicated in two large cohorts of T‐ and B‐cell acute lymphoid leukemia (ALL). Finally, IL17C expression in purified CD4 + CCR4 + CD26‐CD7‐ “ATL‐like” cells from HTLV‐1‐infected individuals and ATL patients was negatively correlated with clonality, underscoring a possible antileukemic/antiproliferative role. In conclusion, decreased RORC expression and downstream signaling might represent an early event in ATL pathogenesis. An antiproliferative IL17C/PCNA link is shared between ATL, T‐ALL and B‐ALL, suggesting (immuno)therapeutic benefit of boosting RORC/IL17 signaling.
- 18 December 2018
- Published by Wiley in International Journal of Cancer
- Vol. 144 (7) , 1664-1675
Open AccessDecreased RORC expression and downstream signaling in HTLV‐1‐associated adult T‐cell lymphoma/leukemia uncovers an antiproliferative IL17 link: A potential target for immunotherapy?
Retinoic acid‐related drugs have shown promising pre‐clinical activity in Adult T‐cell Leukemia/Lymphoma, but RORC signaling has not been explored. Therefore, we investigated transcriptome‐wide interactions of the RORC pathway in HTLV‐1 and ATL, using our own and publicly available gene expression data for ATL and other leukemias. Gene expression data from ATL patients were analyzed using WGCNA to determine gene modules and their correlation to clinical and molecular data. Both PBMCs and CD4+ T‐Cells exhibited decreased RORC expression in four different ATL cohorts. A small subset of RORChi ATL patients was identified with significantly lower pathognomonic CADM1 and HBZ levels but similar levels of other ATL markers (CD4/CD25/CCR4), hinting at a less aggressive ATL subtype. An age‐dependent decrease in RORC expression was found in HTLV‐1‐infected individuals, but not in healthy controls, suggesting an early molecular event predisposing to leukemogenesis. Genes upstream of RORC signaling were members of a proliferative gene module (containing proliferation markers PCNA/Ki67), whereas downstream members clustered in an anti‐proliferative gene module. IL17C transcripts showed the strongest negative correlation to PCNA in both ATL cohorts, which was replicated in two large cohorts of T‐ and B‐cell acute lymphoid leukemia (ALL). Finally, IL17C expression in purified CD4 + CCR4 + CD26‐CD7‐ “ATL‐like” cells from HTLV‐1‐infected individuals and ATL patients was negatively correlated with clonality, underscoring a possible antileukemic/antiproliferative role. In conclusion, decreased RORC expression and downstream signaling might represent an early event in ATL pathogenesis. An antiproliferative IL17C/PCNA link is shared between ATL, T‐ALL and B‐ALL, suggesting (immuno)therapeutic benefit of boosting RORC/IL17 signaling.
- Open Access
Decreased RORC expression and downstream signaling in HTLV-1-associated Adult T-cell Lymphoma/Leukemia uncovers an antiproliferative IL17 link: a potential target for immunotherapy?
Retinoic acid-related drugs have shown promising pre-clinical activity in Adult T-cell Leukemia/Lymphoma (ATL), but RORC (Retinoic acid Orphan Receptor C) signaling has not been explored. Therefore, we investigated transcriptome-wide interactions of the RORC pathway in Human T-cell Leukemia Virus-1 (HTLV-1) infection and ATL, using our own and publicly available gene expression data for ATL and other leukemias, HTLV-1-infected individuals and healthy controls. Gene expression data from ATL patients were analyzed using Weighted Gene Correlation Network Analysis (WGCNA) to determine gene modules and their correlation to clinical and molecular data. Both PBMCs and CD4+ T-cells showed decreased RORC expression in four different ATL cohorts. A small subset of RORChi ATL patients was identified with significantly lower pathognomonic CADM1 and HBZ levels but similar levels of other ATL markers (CD4/CD25/CCR4), hinting at a less aggressive ATL subtype. In addition, an age-dependent decrease in RORC expression was found in HTLV-1-infected individuals, but not in healthy controls, suggesting an early molecular event predisposing to leukemogenesis. Genes upstream of RORC signaling were members of a proliferative gene module (containing proliferation markers PCNA/MKI67), whereas downstream members clustered in an antiproliferative gene module. IL17C transcripts showed the strongest negative correlation to PCNA in both ATL cohorts, which was replicated in two large cohorts of T- and B-cell acute leukemias. In conclusion, decreased RORC expression and downstream signaling might represent an early event in ATL pathogenesis. An antiproliferative IL17C/PCNA link is shared between ATL, T-ALL and B-ALL, suggesting (immuno)therapeutic benefit of boosting RORC/IL17 signaling. Abbreviations: HTLV-1 Human T-cell Leukemia Virus-1 ATL Adult T-cell Leukemia/Lymphoma WGCNA Weighted Gene Correlation Network Analysis ATRA All-trans retinoic acid RARa Retinoic acid receptor alpha RORC Retinoic acid orphan receptor C TBLV Type B Leukomogenic Virus AML Acute Myeloid Leukemia T-ALL T-cell acute lymphoblastic leukemia IL Interleukin PCNA Proliferating cell nuclear antigen ID Infectious Dermatitis
Open AccessDecreased RORC expression and downstream signaling in HTLV-1-associated Adult T-cell Lymphoma/Leukemia uncovers an antiproliferative IL17 link: a potential target for immunotherapy?
Retinoic acid-related drugs have shown promising pre-clinical activity in Adult T-cell Leukemia/Lymphoma (ATL), but RORC (Retinoic acid Orphan Receptor C) signaling has not been explored. Therefore, we investigated transcriptome-wide interactions of the RORC pathway in Human T-cell Leukemia Virus-1 (HTLV-1) infection and ATL, using our own and publicly available gene expression data for ATL and other leukemias, HTLV-1-infected individuals and healthy controls. Gene expression data from ATL patients were analyzed using Weighted Gene Correlation Network Analysis (WGCNA) to determine gene modules and their correlation to clinical and molecular data. Both PBMCs and CD4+ T-cells showed decreased RORC expression in four different ATL cohorts. A small subset of RORChi ATL patients was identified with significantly lower pathognomonic CADM1 and HBZ levels but similar levels of other ATL markers (CD4/CD25/CCR4), hinting at a less aggressive ATL subtype. In addition, an age-dependent decrease in RORC expression was found in HTLV-1-infected individuals, but not in healthy controls, suggesting an early molecular event predisposing to leukemogenesis. Genes upstream of RORC signaling were members of a proliferative gene module (containing proliferation markers PCNA/MKI67), whereas downstream members clustered in an antiproliferative gene module. IL17C transcripts showed the strongest negative correlation to PCNA in both ATL cohorts, which was replicated in two large cohorts of T- and B-cell acute leukemias. In conclusion, decreased RORC expression and downstream signaling might represent an early event in ATL pathogenesis. An antiproliferative IL17C/PCNA link is shared between ATL, T-ALL and B-ALL, suggesting (immuno)therapeutic benefit of boosting RORC/IL17 signaling. Abbreviations: HTLV-1 Human T-cell Leukemia Virus-1 ATL Adult T-cell Leukemia/Lymphoma WGCNA Weighted Gene Correlation Network Analysis ATRA All-trans retinoic acid RARa Retinoic acid receptor alpha RORC Retinoic acid orphan receptor C TBLV Type B Leukomogenic Virus AML Acute Myeloid Leukemia T-ALL T-cell acute lymphoblastic leukemia IL Interleukin PCNA Proliferating cell nuclear antigen ID Infectious Dermatitis
- 15 February 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 200 (4) , 1434-1442
ISG15-Induced IL-10 Is a Novel Anti-Inflammatory Myeloid Axis Disrupted during Active Tuberculosis
IFN-stimulated gene 15 (ISG15) deficiency in humans leads to severe IFNopathies and mycobacterial disease, the latter being previously attributed to its extracellular cytokine-like activity. In this study, we demonstrate a novel role for secreted ISG15 as an IL-10 inducer, unique to primary human monocytes. A balanced ISG15-induced monocyte/IL-10 versus lymphoid/IFN-γ expression, correlating with p38 MAPK and PI3K signaling, was found using targeted in vitro and ex vivo systems analysis of human transcriptomic datasets. The specificity and MAPK/PI3K-dependence of ISG15-induced monocyte IL-10 production was confirmed in vitro using CRISPR/Cas9 knockout and pharmacological inhibitors. Moreover, this ISG15/IL-10 axis was amplified in leprosy but disrupted in human active tuberculosis (TB) patients. Importantly, ISG15 strongly correlated with inflammation and disease severity during active TB, suggesting its potential use as a biomarker, awaiting clinical validation. In conclusion, this study identifies a novel anti-inflammatory ISG15/IL-10 myeloid axis that is disrupted in active TB.
- 15 February 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 200 (4) , 1434-1442
ISG15-Induced IL-10 Is a Novel Anti-Inflammatory Myeloid Axis Disrupted during Active Tuberculosis
IFN-stimulated gene 15 (ISG15) deficiency in humans leads to severe IFNopathies and mycobacterial disease, the latter being previously attributed to its extracellular cytokine-like activity. In this study, we demonstrate a novel role for secreted ISG15 as an IL-10 inducer, unique to primary human monocytes. A balanced ISG15-induced monocyte/IL-10 versus lymphoid/IFN-γ expression, correlating with p38 MAPK and PI3K signaling, was found using targeted in vitro and ex vivo systems analysis of human transcriptomic datasets. The specificity and MAPK/PI3K-dependence of ISG15-induced monocyte IL-10 production was confirmed in vitro using CRISPR/Cas9 knockout and pharmacological inhibitors. Moreover, this ISG15/IL-10 axis was amplified in leprosy but disrupted in human active tuberculosis (TB) patients. Importantly, ISG15 strongly correlated with inflammation and disease severity during active TB, suggesting its potential use as a biomarker, awaiting clinical validation. In conclusion, this study identifies a novel anti-inflammatory ISG15/IL-10 myeloid axis that is disrupted in active TB.
- Open Access
ISG15 induces IL-10 production in human monocytes and is a biomarker of disease severity during active tuberculosis
Interferon stimulated gene 15 (ISG15) deficiency in humans leads to severe interferonopathies and mycobacterial disease, the latter being previously attributed to its extracellular cytokine-like activity. Here, we demonstrate a novel role for secreted ISG15 as an IL-10 inducer, unique to primary human monocytes. Employing ex vivo systems analysis of human transcriptome datasets, we observed a significant correlation of ISG15-induced monocyte IL-10 and lymphocyte IFNγ expression. This effect was associated with p38 MAPK and PI3K signalling in healthy volunteers. The specificity and MAPK/PI3K-dependence of ISG15-induced monocyte IL-10 production was confirmed in vitro using CRISPR/Cas9 knockout and pharmacological inhibitors. Moreover, this ISG15 / IL10 axis was amplified in leprosy but disrupted in human active tuberculosis (TB) patients. Importantly, ISG15 strongly correlated with inflammation and disease severity during active TB. In conclusion, this study identifies a novel anti-inflammatory ISG15/IL-10 myeloid axis that is disrupted in active TB, revealing a potential biomarker for disease severity in this major human disease.
Open AccessISG15 induces IL-10 production in human monocytes and is a biomarker of disease severity during active tuberculosis
Interferon stimulated gene 15 (ISG15) deficiency in humans leads to severe interferonopathies and mycobacterial disease, the latter being previously attributed to its extracellular cytokine-like activity. Here, we demonstrate a novel role for secreted ISG15 as an IL-10 inducer, unique to primary human monocytes. Employing ex vivo systems analysis of human transcriptome datasets, we observed a significant correlation of ISG15-induced monocyte IL-10 and lymphocyte IFNγ expression. This effect was associated with p38 MAPK and PI3K signalling in healthy volunteers. The specificity and MAPK/PI3K-dependence of ISG15-induced monocyte IL-10 production was confirmed in vitro using CRISPR/Cas9 knockout and pharmacological inhibitors. Moreover, this ISG15 / IL10 axis was amplified in leprosy but disrupted in human active tuberculosis (TB) patients. Importantly, ISG15 strongly correlated with inflammation and disease severity during active TB. In conclusion, this study identifies a novel anti-inflammatory ISG15/IL-10 myeloid axis that is disrupted in active TB, revealing a potential biomarker for disease severity in this major human disease.
- Open Access
- 29 January 2014
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 11 (1) , 18
CD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
Background: Human T-cell lymphotropic virus (HTLV-1) is the causative agent of the incapacitating, neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, there are no disease-modifying therapies with long-term clinical benefits or validated biomarkers for clinical follow-up in HAM/TSP. Although CD80 and CD86 costimulatory molecules play prominent roles in immune regulation and reflect disease status in multiple sclerosis (MS), data in HAM/TSP are lacking.Methods: Using flow cytometry, we quantifiedex vivoandin vitroexpression of CD80 and CD86 in PBMCs of healthy controls, HTLV-1-infected individuals with and without HAM/TSP, and MS patients. We hypothesizedex vivoCD80 and CD86 expressions and theirin vitroregulation by interferon (IFN)-α/β mirror similarities between HAM/TSP and MS and hence might reveal clinically useful biomarkers in HAM/TSP.Results: Ex vivoexpression of CD80 and CD86 in T and B cells increased in all HTLV-1 infected individuals, but with a selective defect for B cell CD86 upregulation in HAM/TSP. Despite decreased total B cells with increasing disease duration (p = 0.0003,r = −0.72), CD80+B cells positively correlated with disease severity (p = 0.0017,r = 0.69) in HAM/TSP. B cell CD80 expression was higher in women with HAM/TSP, underscoring that immune markers can reflect the female predominance observed in most autoimmune diseases. In contrast to MS patients, CD80+(p = 0.0001) and CD86+(p = 0.0054) lymphocytes expanded uponin vitroculture in HAM/TSP patients. The expansion of CD80+and CD86+T cells but not B cells was associated with increased proliferation in HTLV-1 infection.In vitrotreatment with IFN-β but not IFN-α resulted in a pronounced increase of B cell CD86 expression in healthy controls, as well as in patients with neuroinflammatory disease (HAM/TSP and MS), similar toin vivotreatment in MS.Conclusions: We propose two novel biomarkers,ex vivoCD80+B cells positively correlating to disease severity and CD86+B cells preferentially induced by IFN-β, which restores defective upregulation in HAM/TSP. This study suggests a role for B cells in HAM/TSP pathogenesis and opens avenues to B cell targeting (with proven clinical benefit in MS) in HAM/TSP but also CD80-directed immunotherapy, unprecedented in both HAM/TSP and MS.
- 29 January 2014
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 11 (1) , 18
Open AccessCD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
Background: Human T-cell lymphotropic virus (HTLV-1) is the causative agent of the incapacitating, neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, there are no disease-modifying therapies with long-term clinical benefits or validated biomarkers for clinical follow-up in HAM/TSP. Although CD80 and CD86 costimulatory molecules play prominent roles in immune regulation and reflect disease status in multiple sclerosis (MS), data in HAM/TSP are lacking.Methods: Using flow cytometry, we quantifiedex vivoandin vitroexpression of CD80 and CD86 in PBMCs of healthy controls, HTLV-1-infected individuals with and without HAM/TSP, and MS patients. We hypothesizedex vivoCD80 and CD86 expressions and theirin vitroregulation by interferon (IFN)-α/β mirror similarities between HAM/TSP and MS and hence might reveal clinically useful biomarkers in HAM/TSP.Results: Ex vivoexpression of CD80 and CD86 in T and B cells increased in all HTLV-1 infected individuals, but with a selective defect for B cell CD86 upregulation in HAM/TSP. Despite decreased total B cells with increasing disease duration (p = 0.0003,r = −0.72), CD80+B cells positively correlated with disease severity (p = 0.0017,r = 0.69) in HAM/TSP. B cell CD80 expression was higher in women with HAM/TSP, underscoring that immune markers can reflect the female predominance observed in most autoimmune diseases. In contrast to MS patients, CD80+(p = 0.0001) and CD86+(p = 0.0054) lymphocytes expanded uponin vitroculture in HAM/TSP patients. The expansion of CD80+and CD86+T cells but not B cells was associated with increased proliferation in HTLV-1 infection.In vitrotreatment with IFN-β but not IFN-α resulted in a pronounced increase of B cell CD86 expression in healthy controls, as well as in patients with neuroinflammatory disease (HAM/TSP and MS), similar toin vivotreatment in MS.Conclusions: We propose two novel biomarkers,ex vivoCD80+B cells positively correlating to disease severity and CD86+B cells preferentially induced by IFN-β, which restores defective upregulation in HAM/TSP. This study suggests a role for B cells in HAM/TSP pathogenesis and opens avenues to B cell targeting (with proven clinical benefit in MS) in HAM/TSP but also CD80-directed immunotherapy, unprecedented in both HAM/TSP and MS.
- Open Access
- 6 June 2011
- Published by Springer Nature in Retrovirology
- Vol. 8 (S1) , A106
B cell costimulatory molecules as potential biomarkers in HAM/TSP
- 6 June 2011
- Published by Springer Nature in Retrovirology
- Vol. 8 (S1) , A106
Open AccessB cell costimulatory molecules as potential biomarkers in HAM/TSP